

### Suven drug ready for human trials

Hyderabad, May 18

12-2 ✓  
Suven Life Sciences Ltd (Suven) today said its clinical drug candidate SUVN-502 completed all the long-term chronic studies essential for US Food and Drug Authority (USFDA) to initiate human phase-II clinical trials. SUVN-502 has been tested in human Phase I trials in Switzerland and demonstrated to be very safe at all doses and durations tested. The next stage will be proof of concept Phase II clinical trials in patients with Alzheimer's/Schizophrenia disease. The potential market opportunity is more than \$20 billion globally said Mr Venkat Jasti, CEO of Suven Life Sciences, in a press release. "We have also received several interests for the product from pharmaceutical companies," he added. -

Our Bureau